An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or MEtastatic Breast Cancer.

Trial Profile

An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or MEtastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Lapatinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 28 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 03 May 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015, as reported by Clinicaltrials.gov.
    • 03 May 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Dec 2015, as reported by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top